

# Matthew J Ellis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6447604/publications.pdf>

Version: 2024-02-01

206  
papers

36,126  
citations

9234

74  
h-index

3476

182  
g-index

216  
all docs

216  
docs citations

216  
times ranked

36091  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1258-1267.	3.2	31
2	Abstract P2-13-24: Distinct HER2 allele specific therapeutic response and preclinical efficacy of poziotinib in metastatic ER+ HER2 mutant breast cancer. <i>Cancer Research</i> , 2022, 82, P2-13-24-P2-13-24.	0.4	0
3	Abstract P5-14-02: Breast cancer clinical trial participation rate among patients of low socioeconomic status at a comprehensive cancer center. <i>Cancer Research</i> , 2022, 82, P5-14-02-P5-14-02.	0.4	0
4	Abstract PD9-03: Pam50 intrinsic subtype and risk of recurrence score (ROR) for the prediction of endocrine (ET) sensitivity and pathologic response to chemotherapy in postmenopausal women with clinical stage II/III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) in the alternate trial (Alliance A011106). <i>Cancer Research</i> , 2022, 82, PD9-03-PD9-03.	0.4	0
5	Abstract P5-07-01: Proteogenomic analysis of differential chemotherapy responses in patient-derived xenografts of triple-negative breast cancer. <i>Cancer Research</i> , 2022, 82, P5-07-01-P5-07-01.	0.4	0
6	Abstract OT2-28-01: A phase 2 study of sitravatinib in metastatic, pre-treated, triple negative breast cancer, NCT # 04123704. <i>Cancer Research</i> , 2022, 82, OT2-28-01-OT2-28-01.	0.4	1
7	Abstract P2-01-13: Longitudinal circulating tumor DNA (ctDNA) monitoring by digital droplet PCR (ddPCR) in metastatic breast cancer. <i>Cancer Research</i> , 2022, 82, P2-01-13-P2-01-13.	0.4	0
8	Cancer proteogenomics: current impact and future prospects. <i>Nature Reviews Cancer</i> , 2022, 22, 298-313.	12.8	79
9	Breast Cancer Treatment Delay in SafetyNet Health Systems, Houston Versus Southeast Brazil. <i>Oncologist</i> , 2022, , .	1.9	1
10	LINC00355 regulates p27KIP expression by binding to MENIN to induce proliferation in late-stage relapse breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 49.	2.3	4
11	PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery. <i>NAR Cancer</i> , 2022, 4, zcac014.	1.6	7
12	Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study. <i>Modern Pathology</i> , 2022, 35, 1362-1369.	2.9	18
13	Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211071.	1.4	6
14	Evaluation of Sensitivity to Endocrine Therapy Index (SET2,3) for Response to Neoadjuvant Endocrine Therapy and Longer-Term Breast Cancer Patient Outcomes (Alliance Z1031). <i>Clinical Cancer Research</i> , 2022, 28, 3287-3295.	3.2	6
15	Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial. <i>Journal of the National Cancer Institute</i> , 2021, 113, 390-399.	3.0	62
16	RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer. <i>British Journal of Cancer</i> , 2021, 124, 191-206.	2.9	16
17	CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity. <i>Nature Cancer</i> , 2021, 2, 34-48.	5.7	48
18	Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer. <i>Cell</i> , 2021, 184, 384-403.e21.	13.5	94

#	ARTICLE	IF	CITATIONS
19	Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2648-2662.	3.2	4
20	Real-world data on neoadjuvant endocrine therapy in ER-positive/HER2-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 753-760.	1.1	3
21	Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. <i>Cancer Cell</i> , 2021, 39, 361-379.e16.	7.7	189
22	Proteogenomic and metabolomic characterization of human glioblastoma. <i>Cancer Cell</i> , 2021, 39, 509-528.e20.	7.7	327
23	The bone microenvironment increases phenotypic plasticity of ER+ breast cancer cells. <i>Developmental Cell</i> , 2021, 56, 1100-1117.e9.	3.1	63
24	Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer. <i>Nature Communications</i> , 2021, 12, 2940.	5.8	14
25	Immunogenomic Profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 187-202.	1.1	24
26	Interaction Between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early-Stage Breast Cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1038-1049.	2.3	5
27	Abstract CT026: A phase II trial of neratinib (NER) or NER plus fulvestrant (FUL) (N+F) in HER2 mutant, non-amplified (HER2mut) metastatic breast cancer (MBC): Part II of MutHER. <i>Cancer Research</i> , 2021, 81, CT026-CT026.	0.4	4
28	Abstract 2490: Optimizing treatment strategy for NF1-depleted estrogen receptor positive breast cancer. , 2021, , .		0
29	A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapy. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 15-23.	1.1	6
30	Abstract 2992: Proteogenomic characterization of triple-negative breast cancer patient-derived xenografts reveals molecular correlates of differential chemotherapy response and potential therapeutic targets to overcome resistance. , 2021, , .		0
31	A proteogenomic portrait of lung squamous cell carcinoma. <i>Cell</i> , 2021, 184, 4348-4371.e40.	13.5	170
32	Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. <i>Nature Communications</i> , 2021, 12, 5086.	5.8	58
33	Proteogenomic characterization of pancreatic ductal adenocarcinoma. <i>Cell</i> , 2021, 184, 5031-5052.e26.	13.5	236
34	Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. <i>Journal of the National Cancer Institute</i> , 2021, 113, 808-819.	3.0	319
35	Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer. <i>Cancer Research</i> , 2021, 81, 6259-6272.	0.4	10
36	Single-nucleotide polymorphism biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancer. <i>Pharmacogenetics and Genomics</i> , 2021, 31, 1-9.	0.7	0

#	ARTICLE	IF	CITATIONS
37	Concurrent Chemo-radiation As a Means of Achieving Pathologic Complete Response in Triple Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2021, , .	1.1	0
38	Research-based PAM50 signature and long-term breast cancer survival. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 197-206.	1.1	53
39	Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 3-10.	1.1	39
40	Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy. <i>JAMA Oncology</i> , 2020, 6, 367.	3.4	100
41	Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance). <i>Journal of the National Cancer Institute</i> , 2020, 112, 737-746.	3.0	51
42	CDK4/6 Inhibitor Biomarker Research: Are We Barking Up the Wrong Tree?. <i>Clinical Cancer Research</i> , 2020, 26, 3-5.	3.2	22
43	Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy. <i>Cell</i> , 2020, 183, 1436-1456.e31.	13.5	273
44	Integrated Proteogenomic Characterization across Major Histological Types of Pediatric Brain Cancer. <i>Cell</i> , 2020, 183, 1962-1985.e31.	13.5	177
45	Proteomic Resistance Biomarkers for PI3K Inhibitor in Triple Negative Breast Cancer Patient-Derived Xenograft Models. <i>Cancers</i> , 2020, 12, 3857.	1.7	8
46	Evidence-based guidelines for managing patients with primary ER+ HER2~ breast cancer deferred from surgery due to the COVID-19 pandemic. <i>Npj Breast Cancer</i> , 2020, 6, 21.	2.3	42
47	Response to J~z~quel, Patsouris, Guette, et al. <i>Journal of the National Cancer Institute</i> , 2020, 112, 865-865.	3.0	0
48	Neurofibromin Is an Estrogen Receptor-~ Transcriptional Co-repressor in Breast Cancer. <i>Cancer Cell</i> , 2020, 37, 387-402.e7.	7.7	59
49	Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma. <i>Cell</i> , 2020, 182, 200-225.e35.	13.5	410
50	Proteogenomic Characterization of Endometrial Carcinoma. <i>Cell</i> , 2020, 180, 729-748.e26.	13.5	296
51	Microscaled proteogenomic methods for precision oncology. <i>Nature Communications</i> , 2020, 11, 532.	5.8	78
52	ESR1 Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor~ Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor Therapy. <i>Frontiers in Oncology</i> , 2020, 10, 342.	1.3	6
53	Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor ~. <i>Clinical Cancer Research</i> , 2020, 26, 2986-2996.	3.2	17
54	Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action. <i>JCI Insight</i> , 2020, 5, .	2.3	16

#	ARTICLE	IF	CITATIONS
55	Abstract PD7-03: Adaptive kinome reprogramming in endocrine therapy resistant metastatic breast cancer. , 2020, , .		0
56	Abstract P2-11-08: ESR1 mutations are not a mechanism of primary resistance to aromatase inhibitors in ER-positive breast cancer treated with neoadjuvant endocrine therapy. , 2020, , .		0
57	Abstract P6-04-04: Functional characterization ofESR1fusions in breast cancer. , 2020, , .		1
58	Abstract P2-16-03: Neoadjuvant treatment of triple negative breast cancer patients with docetaxel and carboplatin to assess anti-tumor activity. , 2020, , .		0
59	Abstract P6-04-20: Proteogenomic analysis of estrogen modulated breast cancer metastasis. , 2020, , .		0
60	Abstract GS2-05: Microscaled proteogenomic methods for precision oncology. , 2020, , .		0
61	Regulated Phosphosignaling Associated with Breast Cancer Subtypes and Druggability*. Molecular and Cellular Proteomics, 2019, 18, 1630-1650.	2.5	14
62	Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia. Breast Cancer Research and Treatment, 2019, 177, 427-435.	1.1	11
63	Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. New England Journal of Medicine, 2019, 380, 2395-2405.	13.9	349
64	miRNAs and Long-term Breast Cancer Survival: Evidence from the WHEL Study. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1525-1533.	1.1	14
65	Copy number alterations associated with clinical features in an underrepresented population with breast cancer. Molecular Genetics & Genomic Medicine, 2019, 7, e00750.	0.6	7
66	A meta-analysis of clinical benefit rates for fulvestrant 500Âmg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer. Breast Cancer, 2019, 26, 703-711.	1.3	5
67	Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic Opportunities. Cell, 2019, 177, 1035-1049.e19.	13.5	498
68	Deep sequencing across germline genome-wide association study signals relating to breast cancer events in women receiving aromatase inhibitors for adjuvant therapy of early breast cancer. Pharmacogenetics and Genomics, 2019, 29, 183-191.	0.7	0
69	Endocrine therapy resistance: new insights. Breast, 2019, 48, S26-S30.	0.9	60
70	Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy. JAMA Oncology, 2019, 5, 45.	3.4	16
71	Endocrine Therapy in Clinical Practice. Cancer Drug Discovery and Development, 2019, , 215-240.	0.2	1
72	<i>ESR1</i> alterations and metastasis in estrogen receptor positive breast cancer. Journal of Cancer Metastasis and Treatment, 2019, 2019, .	0.5	62

#	ARTICLE	IF	CITATIONS
73	Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers. <i>Cancer Research</i> , 2018, 78, 2732-2746.	0.4	52
74	Current Status of Neoadjuvant Endocrine Therapy in Early Stage Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2018, 19, 23.	1.3	23
75	Progression-free survival results in postmenopausal Asian women: subgroup analysis from a phase III randomized trial of fulvestrant 500Âmg vs anastrozole 1Âmg for hormone receptor-positive advanced breast cancer (FALCON). <i>Breast Cancer</i> , 2018, 25, 356-364.	1.3	8
76	Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer. <i>Nature Medicine</i> , 2018, 24, 505-511.	15.2	47
77	Health-related quality of life from the FALCON phaseÂIII randomised trial of fulvestrant 500Âmg versus anastrozole for hormone receptor-positive advanced breast cancer. <i>European Journal of Cancer</i> , 2018, 94, 206-215.	1.3	14
78	Effects of Celecoxib and Low-dose Aspirin on Outcomes in Adjuvant Aromatase Inhibitor-Treated Patients: CCTG MA.27. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1003-1008.	3.0	19
79	TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2018, 78, 489-500.	0.4	122
80	ESR1 fusions drive endocrine therapy resistance and metastasis in breast cancer. <i>Molecular and Cellular Oncology</i> , 2018, 5, e1526005.	0.3	16
81	DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E11978-E11987.	3.3	40
82	Long noncoding RNA MALAT1 suppresses breast cancer metastasis. <i>Nature Genetics</i> , 2018, 50, 1705-1715.	9.4	561
83	The prognostic effects of somatic mutations in ER-positive breast cancer. <i>Nature Communications</i> , 2018, 9, 3476.	5.8	89
84	Cancer incidence and mortality rates and trends in Trinidad and Tobago. <i>BMC Cancer</i> , 2018, 18, 712.	1.1	19
85	Comprehensive Profiling of DNA Repair Defects in Breast Cancer Identifies a Novel Class of Endocrine Therapy Resistance Drivers. <i>Clinical Cancer Research</i> , 2018, 24, 4887-4899.	3.2	74
86	FGFR1-Activated Translation of WNT Pathway Components with Structured 5â€² UTRs Is Vulnerable to Inhibition of EIF4A-Dependent Translation Initiation. <i>Cancer Research</i> , 2018, 78, 4229-4240.	0.4	22
87	Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer. <i>Cell Reports</i> , 2018, 24, 1434-1444.e7.	2.9	73
88	Identifying biomarkers of breast cancer micrometastatic disease in bone marrow using a patient-derived xenograft mouse model. <i>Breast Cancer Research</i> , 2018, 20, 2.	2.2	17
89	Proteomic profiling identifies key coactivators utilized by mutant ERÎ± proteins as potential new therapeutic targets. <i>Oncogene</i> , 2018, 37, 4581-4598.	2.6	51
90	gpGrouper: A Peptide Grouping Algorithm for Gene-Centric Inference and Quantitation of Bottom-Up Proteomics Data. <i>Molecular and Cellular Proteomics</i> , 2018, 17, 2270-2283.	2.5	71

#	ARTICLE	IF	CITATIONS
91	Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 111-121.	13.9	1,558
92	ZB716, a steroidal selective estrogen receptor degrader (SERD), is orally efficacious in blocking tumor growth in mouse xenograft models. <i>Oncotarget</i> , 2018, 9, 6924-6937.	0.8	27
93	DNA damage repair defects as a new class of endocrine treatment resistance driver. <i>Oncotarget</i> , 2018, 9, 36252-36253.	0.8	37
94	Endocrine therapy for ER-positive/HER2-negative metastatic breast cancer. <i>Chinese Clinical Oncology</i> , 2018, 7, 25-25.	0.4	24
95	Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). <i>Journal of Clinical Oncology</i> , 2017, 35, 1061-1069.	0.8	254
96	Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2017, 77, 2476-2487.	0.4	173
97	NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4055-4065.	3.2	243
98	Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor-positive breast cancer: NCIC CTG MA.27. <i>Cancer</i> , 2017, 123, 2444-2451.	2.0	11
99	Breast Cancer Neoantigens Can Induce CD8+ T-Cell Responses and Antitumor Immunity. <i>Cancer Immunology Research</i> , 2017, 5, 516-523.	1.6	74
100	Current Challenges Associated With Next-Generation Sequencing of Breast Cancer—Reply. <i>JAMA Oncology</i> , 2017, 3, 1284.	3.4	0
101	Development of a Ki-67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 355-364.	1.1	26
102	Proteogenomic integration reveals therapeutic targets in breast cancer xenografts. <i>Nature Communications</i> , 2017, 8, 14864.	5.8	112
103	An mRNA Gene Expression-Based Signature to Identify FGFR1-Amplified Estrogen Receptor-Positive Breast Tumors. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 147-161.	1.2	11
104	Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 7288-7300.	3.2	29
105	Breast tumors educate the proteome of stromal tissue in an individualized but coordinated manner. <i>Science Signaling</i> , 2017, 10, .	1.6	25
106	A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 6823-6832.	3.2	66
107	CDK4/6 inhibition triggers anti-tumour immunity. <i>Nature</i> , 2017, 548, 471-475.	13.7	998
108	Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer. <i>Cancer Discovery</i> , 2017, 7, 1168-1183.	7.7	58

#	ARTICLE	IF	CITATIONS
109	Quality Assessments of Long-Term Quantitative Proteomic Analysis of Breast Cancer Xenograft Tissues. <i>Journal of Proteome Research</i> , 2017, 16, 4523-4530.	1.8	17
110	Neratinib Efficacy and Circulating Tumor DNA Detection of <i>HER2</i> Mutations in <i>HER2</i> Nonamplified Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5687-5695.	3.2	170
111	Lessons in precision oncology from neoadjuvant endocrine therapy trials in ER+ breast cancer. <i>Breast</i> , 2017, 34, S104-S107.	0.9	24
112	The Role of Genetic Testing in the Selection of Therapy for Breast Cancer. <i>JAMA Oncology</i> , 2017, 3, 262.	3.4	11
113	Neonatal Encephalopathy With Group B Streptococcal Disease Worldwide: Systematic Review, Investigator Group Datasets, and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2017, 65, S173-S189.	2.9	51
114	An interview with Professor Matthew Ellis at the NCRI 2017 Cancer Conference. <i>Breast Cancer Management</i> , 2017, 6, 109-111.	0.2	0
115	Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib. <i>Breast Cancer Research</i> , 2017, 19, 123.	2.2	53
116	Avoidance of Negative Results in Adjuvant Endocrine Therapy Trials for Estrogen Receptor-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 2718-2719.	0.8	6
117	Health-related quality of life from a phase 3 randomized trial of fulvestrant 500 mg vs anastrozole for hormone receptor-positive advanced breast cancer (FALCON).. <i>Journal of Clinical Oncology</i> , 2017, 35, 1048-1048.	0.8	3
118	Defects in mismatch repair: the Achilles heel of estrogen receptor positive breast cancer with intrinsic endocrine therapy resistance?. <i>Oncoscience</i> , 2017, 4, 77-78.	0.9	4
119	Phase II trial of neoadjuvant (neo) palbociclib (Palbo) plus anastrozole (ana) in endocrine resistant clinical stage 2/3 estrogen receptor positive and HER2 negative (ER+ HER2-) breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS592-TPS592.	0.8	0
120	Reply to T. Reinert et al. <i>Journal of Clinical Oncology</i> , 2016, 34, 1960-1961.	0.8	0
121	Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy. <i>Cancer Research</i> , 2016, 76, 7012-7023.	0.4	47
122	PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance). <i>Npj Breast Cancer</i> , 2016, 2, .	2.3	80
123	Patient-derived xenograft (PDX) models in basic and translational breast cancer research. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 547-573.	2.7	189
124	Proteogenomics connects somatic mutations to signalling in breast cancer. <i>Nature</i> , 2016, 534, 55-62.	13.7	1,384
125	Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). <i>Journal of Clinical Oncology</i> , 2016, 34, 2602-2609.	0.8	101
126	Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology</i> , 2016, 17, 811-821.	5.1	239



#	ARTICLE	IF	CITATIONS
127	Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. <i>Lancet</i> , The, 2016, 388, 2997-3005.	6.3	435
128	Reactivation of p53 by MDM2 Inhibitor MI-77301 for the Treatment of Endocrine-Resistant Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2887-2893.	1.9	29
129	Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers. <i>Nature Communications</i> , 2016, 7, 12498.	5.8	69
130	A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2650-2658.	3.2	63
131	A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 1583-1591.	3.2	86
132	An Analysis of the Sensitivity of Proteogenomic Mapping of Somatic Mutations and Novel Splicing Events in Cancer. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 1060-1071.	2.5	104
133	Mammary Ductal Environment Is Necessary for Faithful Maintenance of Estrogen Signaling in ER + Breast Cancer. <i>Cancer Cell</i> , 2016, 29, 249-250.	7.7	6
134	Prognostic and Predictive Biomarkers of Endocrine Responsiveness for Estrogen Receptor Positive Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2016, 882, 125-154.	0.8	29
135	Recommendations for the Generation, Quantification, Storage, and Handling of Peptides Used for Mass Spectrometry-Based Assays. <i>Clinical Chemistry</i> , 2016, 62, 48-69.	1.5	187
136	Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 29.	3.4	68
137	QuantFusion: Novel Unified Methodology for Enhanced Coverage and Precision in Quantifying Global Proteomic Changes in Whole Tissues. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 740-751.	2.5	8
138	RUNX1 prevents oestrogen-mediated AXIN1 suppression and $\beta$ -catenin activation in ER-positive breast cancer. <i>Nature Communications</i> , 2016, 7, 10751.	5.8	61
139	HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1061-1064.	2.3	70
140	Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 5121-5130.	3.2	126
141	Associations among ancestry, geography and breast cancer incidence, mortality, and survival in Trinidad and Tobago. <i>Cancer Medicine</i> , 2015, 4, 1742-1753.	1.3	17
142	Patterns and functional implications of rare germline variants across 12 cancer types. <i>Nature Communications</i> , 2015, 6, 10086.	5.8	243
143	Treatment-Associated Musculoskeletal and Vasomotor Symptoms and Relapse-Free Survival in the NCIC CTG MA.27 Adjuvant Breast Cancer Aromatase Inhibitor Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 265-271.	0.8	36
144	Mechanisms of aromatase inhibitor resistance. <i>Nature Reviews Cancer</i> , 2015, 15, 261-275.	12.8	319

#	ARTICLE	IF	CITATIONS
145	Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression. <i>Oncologist</i> , 2015, 20, 474-482.	1.9	145
146	Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 2005-2014.	13.9	1,146
147	Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance). <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	52
148	Development and verification of the PAM50-based Prosigna breast cancer gene signature assay. <i>BMC Medical Genomics</i> , 2015, 8, 54.	0.7	352
149	Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 3781-3787.	0.8	200
150	Abstract P4-11-13: Validation of the preoperative endocrine prognostic index in the ACOSOG (Alliance) Z1031 neoadjuvant aromatase inhibitor trial. , 2015, , .		2
151	The ALTERNATE trial: assessing a biomarker driven strategy for the treatment of post-menopausal women with ER+/Her2- invasive breast cancer. <i>Chinese Clinical Oncology</i> , 2015, 4, 34.	0.4	45
152	SciClone: Inferring Clonal Architecture and Tracking the Spatial and Temporal Patterns of Tumor Evolution. <i>PLoS Computational Biology</i> , 2014, 10, e1003665.	1.5	400
153	Safety and Preliminary Evidence of Biologic Efficacy of a Mammaglobin-A DNA Vaccine in Patients with Stable Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 5964-5975.	3.2	70
154	Ischemia in Tumors Induces Early and Sustained Phosphorylation Changes in Stress Kinase Pathways but Does Not Affect Global Protein Levels. <i>Molecular and Cellular Proteomics</i> , 2014, 13, 1690-1704.	2.5	323
155	A phase I study of the AKT inhibitor MK-2206 plus hormonal therapy in postmenopausal women with estrogen receptor positive (ER+) metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 553-553.	0.8	0
156	Mutational analysis of breast cancer: Guiding personalized treatments. <i>Breast</i> , 2013, 22, S19-S21.	0.9	16
157	Combined Targeting of mTOR and AKT Is an Effective Strategy for Basal-like Breast Cancer in Patient-Derived Xenograft Models. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 1665-1675.	1.9	38
158	Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer. <i>Cancer Discovery</i> , 2013, 3, 224-237.	7.7	697
159	The Genomic Landscape of Breast Cancer as a Therapeutic Roadmap. <i>Cancer Discovery</i> , 2013, 3, 27-34.	7.7	200
160	Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts. <i>Cell Reports</i> , 2013, 4, 1116-1130.	2.9	539
161	PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 457-466.	1.1	96
162	Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27â€”A Randomized Controlled Phase III Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 1398-1404.	0.8	218

#	ARTICLE	IF	CITATIONS
163	Molecular Pathways: Extracting Medical Knowledge from High-Throughput Genomic Data. <i>Clinical Cancer Research</i> , 2013, 19, 3114-3120.	3.2	12
164	Connecting Genomic Alterations to Cancer Biology with Proteomics: The NCI Clinical Proteomic Tumor Analysis Consortium. <i>Cancer Discovery</i> , 2013, 3, 1108-1112.	7.7	243
165	Intrapartum-related neonatal encephalopathy incidence and impairment at regional and global levels for 2010 with trends from 1990. <i>Pediatric Research</i> , 2013, 74, 50-72.	1.1	442
166	Abstract LB-236: Patient derived xenografts as high-fidelity genomic models for advanced breast cancer.., 2013,, .		0
167	A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen. <i>Clinical Cancer Research</i> , 2012, 18, 4465-4472.	3.2	258
168	Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial. <i>Clinical Cancer Research</i> , 2012, 18, 2402-2412.	3.2	132
169	A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints. <i>Lancet Oncology</i> , The, 2012, 13, e240-e248.	5.1	64
170	Fulvestrant 500Âmg versus anastrozole 1Âmg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized â€˜FIRStâ€™ study. <i>Breast Cancer Research and Treatment</i> , 2012, 136, 503-511.	1.1	154
171	Whole-genome analysis informs breast cancer response to aromatase inhibition. <i>Nature</i> , 2012, 486, 353-360.	13.7	922
172	PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers. <i>BMC Medical Genomics</i> , 2012, 5, 44.	0.7	250
173	Practical implications of gene-expression-based assays for breast oncologists. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 48-57.	12.5	242
174	Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. <i>Journal of Clinical Investigation</i> , 2012, 122, 1541-1552.	3.9	187
175	Clinical and correlative science results in a phase II study of UCN-01in combination with irinotecan in recurrent triple-negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 3047-3047.	0.8	2
176	Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1656-1664.	3.0	1,505
177	Importance of PI3-kinase pathway in response/resistance to aromatase inhibitors. <i>Steroids</i> , 2011, 76, 750-752.	0.8	42
178	Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. <i>Breast Cancer Research</i> , 2011, 13, R21.	2.2	162
179	Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptorâ€™Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtypeâ€™ACOSOG Z1031. <i>Journal of Clinical Oncology</i> , 2011, 29, 2342-2349.	0.8	470
180	Phosphatidylinositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 119, 379-390.	1.1	122

#	ARTICLE	IF	CITATIONS
181	Genome remodelling in a basal-like breast cancer metastasis and xenograft. <i>Nature</i> , 2010, 464, 999-1005.	13.7	1,077
182	A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 5222-5232.	3.2	676
183	Taxane-Based Chemotherapy for Node-Positive Breast Cancer – Take-Home Lessons. <i>New England Journal of Medicine</i> , 2010, 362, 2122-2124.	13.9	2
184	Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 12909-12914.	3.3	105
185	Activity of Fulvestrant 500 mg Versus Anastrozole 1 mg As First-Line Treatment for Advanced Breast Cancer: Results From the FIRST Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 4530-4535.	0.8	273
186	Topoisomerase III $\pm$ Amplification Does Not Predict Benefit From Dose-Intense Cyclophosphamide, Doxorubicin, and Fluorouracil Therapy in <i>HER2</i> -Amplified Early Breast Cancer: Results of CALGB 8541/150013. <i>Journal of Clinical Oncology</i> , 2009, 27, 3430-3436.	0.8	45
187	Lower-Dose vs High-Dose Oral Estradiol Therapy of Hormone Receptor-Positive, Aromatase Inhibitor-Resistant Advanced Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 774.	3.8	252
188	<i>PIK3CA</i> and <i>PIK3CB</i> Inhibition Produce Synthetic Lethality when Combined with Estrogen Deprivation in Estrogen Receptor-Positive Breast Cancer. <i>Cancer Research</i> , 2009, 69, 3955-3962.	0.4	198
189	Improved Surgical Outcomes for Breast Cancer Patients Receiving Neoadjuvant Aromatase Inhibitor Therapy: Results from a Multicenter Phase II Trial. <i>Journal of the American College of Surgeons</i> , 2009, 208, 906-914.	0.2	74
190	Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial. <i>Breast Cancer Research and Treatment</i> , 2009, 116, 371-378.	1.1	38
191	Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes. <i>Journal of Clinical Oncology</i> , 2009, 27, 1160-1167.	0.8	3,730
192	Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2009, 101, 736-750.	3.0	1,844
193	ESR1 gene amplification in breast cancer: a common phenomenon?. <i>Nature Genetics</i> , 2008, 40, 806-807.	9.4	62
194	Outcome Prediction for Estrogen Receptor-Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics. <i>Journal of the National Cancer Institute</i> , 2008, 100, 1380-1388.	3.0	566
195	HER2 and Response to Paclitaxel in Node-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2007, 357, 1496-1506.	13.9	531
196	A luminal breast cancer genome atlas: Progress and barriers. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2007, 106, 125-129.	1.2	7
197	Femara <sup>®</sup> and the future: tailoring treatment and combination therapies with Femara. <i>Breast Cancer Research and Treatment</i> , 2007, 105, 105-115.	1.1	13
198	Letrozole in the neoadjuvant setting: the P024 trial. <i>Breast Cancer Research and Treatment</i> , 2007, 105, 33-43.	1.1	111

#	ARTICLE	IF	CITATIONS
199	The molecular portraits of breast tumors are conserved across microarray platforms. <i>BMC Genomics</i> , 2006, 7, 96.	1.2	1,169
200	Estrogen-Independent Proliferation Is Present in Estrogen-Receptor HER2-Positive Primary Breast Cancer After Neoadjuvant Letrozole. <i>Journal of Clinical Oncology</i> , 2006, 24, 3019-3025.	0.8	170
201	Importance of correlative science in advancing hormonal therapy and a new clinical paradigm for neoadjuvant therapy. <i>Annals of Surgical Oncology</i> , 2004, 11, 9S-17S.	0.7	9
202	Neoadjuvant Endocrine Therapy as a Drug Development Strategy. <i>Clinical Cancer Research</i> , 2004, 10, 391s-395s.	3.2	15
203	Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women. <i>Cancer</i> , 2003, 98, 229-238.	2.0	305
204	Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. <i>Cancer Research</i> , 2003, 63, 6523-31.	0.4	158
205	Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1 and/or ErbB-2 Positive, Estrogen Receptor Positive Primary Breast Cancer: Evidence From a Phase III Randomized Trial. <i>Journal of Clinical Oncology</i> , 2001, 19, 3808-3816.	0.8	1,027
206	Outcome at 1 year of neonatal encephalopathy in Kathmandu, Nepal. <i>Developmental Medicine and Child Neurology</i> , 1999, 41, 689-695.	1.1	42